Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Neurocrine Biosciences Inc (NBIX)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc.
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 914475.
Total stock buying since 2015: $0.
Total stock sales since 2015: $574,950,313.
Total stock option exercises since 2015: $118,701,672.
Table 3. Detailed insider trading at Neurocrine Biosciences Inc (NBIX) , Part 5
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2018-06-20 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 23,000 | 19.59 | 450,570 |
| 2018-06-14 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,785 | 100.00 | 278,500 |
| 2018-06-14 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 2,785 | 19.59 | 54,558 |
| 2018-06-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 84,178 | 99.68 | 8,391,031 |
| 2018-06-13 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 84,178 | 14.12 | 1,188,593 |
| 2018-06-13 | Lyons Gary A (Director) | Sale | 15,000 | 99.24 | 1,488,555 |
| 2018-06-11 | Sherwin Stephen A (Director) | Sale | 10,000 | 98.44 | 984,419 |
| 2018-06-01 | Benevich Eric (Chief Commercial Officer) | Sale | 12,350 | 97.34 | 1,202,161 |
| 2018-05-07 | Nevinny Corinne H (Director) | Sale | 5,000 | 83.12 | 415,625 |
| 2018-05-02 | Nevinny Corinne H (Director) | Option Ex | 15,000 | 7.05 | 105,750 |
| 2018-05-01 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 126,832 | 80.75 | 10,241,684 |
| 2018-05-01 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 126,832 | 5.76 | 730,552 |
| 2018-05-01 | Pops Richard F (Director) | Option Ex | 15,000 | 7.05 | 105,750 |
| 2018-04-26 | Sherwin Stephen A (Director) | Option Ex | 15,000 | 7.05 | 105,750 |
| 2018-04-03 | Lyons Gary A (Director) | Option Ex | 15,000 | 7.05 | 105,750 |
| 2018-03-05 | Gano Kyle (Chief Business Development Officer) | Sale | 23,650 | 90.00 | 2,128,500 |
| 2018-03-05 | Gano Kyle (Chief Business Development Officer) | Option Ex | 23,650 | 8.65 | 204,572 |
| 2018-03-05 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,979 | 88.47 | 175,090 |
| 2018-03-05 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 1,979 | 18.15 | 35,918 |
| 2018-03-05 | Bozigian Haig P. (Chief Development Officer) | Sale | 75,873 | 90.00 | 6,828,570 |
| 2018-03-05 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 75,873 | 24.50 | 1,858,888 |
| 2018-02-15 | Lyons Gary A (Director) | Sale | 5,000 | 84.67 | 423,340 |
| 2018-02-12 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 14,593 | 80.00 | 1,167,454 |
| 2018-02-12 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 14,593 | 8.66 | 126,375 |
| 2018-02-09 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 71,775 | 77.98 | 5,596,727 |
| 2018-02-09 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 71,775 | 8.66 | 621,571 |
| 2018-02-06 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 100,000 | 80.07 | 8,006,600 |
| 2018-02-06 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 100,000 | 5.76 | 576,000 |
| 2018-02-05 | Benevich Eric (Chief Commercial Officer) | Sale | 820 | 83.14 | 68,173 |
| 2018-02-05 | Gano Kyle (Chief Business Development Officer) | Sale | 2,046 | 83.08 | 169,987 |
| 2018-02-05 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 960 | 83.19 | 79,862 |
| 2018-02-05 | Lippoldt Darin (Chief Legal Officer) | Sale | 2,737 | 83.12 | 227,504 |
| 2018-02-05 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 1,979 | 18.15 | 35,918 |
| 2018-02-05 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,046 | 83.12 | 170,071 |
| 2018-02-05 | Bozigian Haig P. (Chief Development Officer) | Sale | 2,262 | 83.12 | 188,026 |
| 2018-02-05 | Obrien Christopher Flint (Former Chief Medical Officer) | Sale | 2,613 | 83.20 | 217,414 |
| 2018-02-05 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 5,983 | 83.27 | 498,216 |
| 2018-02-05 | Lyons Gary A (Director) | Sale | 5,000 | 83.08 | 415,379 |
| 2018-01-24 | Rastetter William H (Director) | Sale | 9,500 | 90.00 | 855,000 |
| 2018-01-24 | Rastetter William H (Director) | Option Ex | 20,000 | 7.05 | 141,000 |
| 2018-01-16 | Gano Kyle (Chief Business Development Officer) | Sale | 1,625 | 79.05 | 128,459 |
| 2018-01-16 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 79.12 | 128,563 |
| 2018-01-16 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 79.12 | 128,574 |
| 2018-01-16 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 79.14 | 138,498 |
| 2018-01-16 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,750 | 78.89 | 295,818 |
| 2018-01-03 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,979 | 79.36 | 157,053 |
| 2018-01-03 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 1,979 | 18.15 | 35,918 |
| 2018-01-02 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 18,084 | 77.52 | 1,401,817 |
| 2018-01-02 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 18,084 | 15.45 | 279,397 |
| 2017-12-28 | Lippoldt Darin (Chief Legal Officer) | Sale | 15,237 | 75.00 | 1,142,775 |
| 2017-12-28 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 15,237 | 18.15 | 276,551 |
| 2017-12-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 2,955 | 75.00 | 221,625 |
| 2017-12-08 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 2,955 | 18.15 | 53,633 |
| 2017-12-04 | Lippoldt Darin (Chief Legal Officer) | Sale | 6,279 | 75.04 | 471,157 |
| 2017-12-04 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 6,279 | 18.15 | 113,963 |
| 2017-12-01 | Lyons Gary A (Director) | Sale | 10,000 | 72.92 | 729,180 |
| 2017-11-15 | Lippoldt Darin (Chief Legal Officer) | Sale | 9,900 | 73.05 | 723,195 |
| 2017-11-15 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 9,900 | 18.15 | 179,685 |
| 2017-11-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 30,000 | 74.58 | 2,237,340 |
| 2017-11-02 | Gano Kyle (Chief Business Development Officer) | Sale | 24,818 | 71.05 | 1,763,318 |
| 2017-11-02 | Gano Kyle (Chief Business Development Officer) | Option Ex | 24,818 | 8.65 | 214,799 |
| 2017-11-02 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 52,817 | 69.71 | 3,681,661 |
| 2017-11-02 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 52,817 | 8.65 | 457,131 |
| 2017-10-02 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 6,925 | 61.04 | 422,702 |
| 2017-10-02 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 6,925 | 8.65 | 59,901 |
| 2017-09-06 | Gano Kyle (Chief Business Development Officer) | Sale | 25,000 | 60.00 | 1,500,000 |
| 2017-09-06 | Gano Kyle (Chief Business Development Officer) | Option Ex | 25,000 | 8.65 | 216,249 |
| 2017-09-06 | Lippoldt Darin (Chief Legal Officer) | Sale | 100 | 60.00 | 6,000 |
| 2017-09-06 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 100 | 18.15 | 1,814 |
| 2017-09-06 | Bozigian Haig P. (Chief Development Officer) | Sale | 26,250 | 60.00 | 1,575,000 |
| 2017-09-06 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 26,250 | 14.12 | 370,650 |
| 2017-09-05 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 52,817 | 57.50 | 3,036,977 |
| 2017-09-05 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 52,817 | 8.66 | 457,395 |
| 2017-08-09 | Lippoldt Darin (Chief Legal Officer) | Sale | 5,000 | 55.00 | 275,000 |
| 2017-08-09 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 5,000 | 18.15 | 90,750 |
| 2017-08-09 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 15,354 | 55.00 | 844,470 |
| 2017-08-09 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 15,354 | 5.76 | 88,439 |
| 2017-08-04 | Bozigian Haig P. (Chief Development Officer) | Sale | 22,500 | 50.00 | 1,125,000 |
| 2017-08-04 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 45,000 | 7.21 | 324,450 |
| 2017-07-27 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 8,734 | 50.00 | 436,700 |
| 2017-07-27 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 8,734 | 8.65 | 75,549 |
| 2017-05-23 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 53.39 | 533,900 |
| 2017-05-19 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 4,980 | 54.00 | 268,920 |
| 2017-05-19 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 4,980 | 15.45 | 76,941 |
| 2017-05-18 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 4,980 | 53.26 | 265,234 |
| 2017-05-18 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 4,980 | 15.45 | 76,941 |
| 2017-05-18 | Lippoldt Darin (Chief Legal Officer) | Sale | 10,000 | 53.27 | 532,700 |
| 2017-05-18 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 10,000 | 18.15 | 181,500 |
| 2017-05-18 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 105,634 | 53.32 | 5,632,404 |
| 2017-05-18 | Obrien Christopher Flint (Chief Medical Officer) | Option Ex | 105,634 | 6.73 | 710,599 |
| 2017-05-05 | Nevinny Corinne H (Director) | Sale | 5,000 | 53.98 | 269,900 |
| 2017-05-03 | Nevinny Corinne H (Director) | Option Ex | 15,000 | 3.40 | 51,000 |
| 2017-05-03 | Pops Richard F (Director) | Option Ex | 15,000 | 3.40 | 51,000 |
| 2017-05-02 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 55.00 | 550,000 |
| 2017-05-02 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 21,739 | 53.23 | 1,157,166 |
| 2017-05-02 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 21,739 | 2.59 | 56,304 |
| 2017-05-01 | Gano Kyle (Chief Business Development Officer) | Sale | 15,000 | 54.00 | 810,000 |
| 2017-05-01 | Gano Kyle (Chief Business Development Officer) | Option Ex | 15,000 | 2.59 | 38,850 |
| 2017-04-12 | Gano Kyle (Chief Business Development Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Lippoldt Darin (Chief Legal Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Bozigian Haig P. (Chief Development Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 13,065 | 50.82 | 663,963 |
| 2017-04-12 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 19,596 | 50.82 | 995,868 |
| 2017-04-12 | Mollica Joseph A (Director) | Option Ex | 20,000 | 3.40 | 68,000 |
| 2017-02-14 | Lyons Gary A (Director) | Option Ex | 15,000 | 3.40 | 51,000 |
| 2017-02-08 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 64,161 | 2.59 | 166,176 |
| 2017-02-07 | Benevich Eric (Chief Commercial Officer) | Sale | 132 | 44.65 | 5,893 |
| 2017-02-07 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 116 | 44.61 | 5,174 |
| 2017-02-07 | Lippoldt Darin (Chief Legal Officer) | Sale | 132 | 44.62 | 5,889 |
| 2017-02-07 | Sherwin Stephen A (Director) | Option Ex | 15,000 | 3.40 | 51,000 |
| 2017-02-06 | Benevich Eric (Chief Commercial Officer) | Sale | 821 | 43.11 | 35,393 |
| 2017-02-06 | Gano Kyle (Chief Business Development Officer) | Sale | 727 | 43.15 | 31,370 |
| 2017-02-06 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 727 | 43.15 | 31,370 |
| 2017-02-06 | Lippoldt Darin (Chief Legal Officer) | Sale | 821 | 43.13 | 35,409 |
| 2017-02-06 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 727 | 43.13 | 31,355 |
| 2017-02-06 | Bozigian Haig P. (Chief Development Officer) | Sale | 963 | 43.14 | 41,543 |
| 2017-02-06 | Coughlin Timothy P (Chief Financial Officer) | Sale | 963 | 43.14 | 41,543 |
| 2017-02-06 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,206 | 43.17 | 52,063 |
| 2017-02-06 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,010 | 43.18 | 129,971 |
| 2017-02-03 | Gano Kyle (Chief Business Development Officer) | Sale | 1,375 | 42.57 | 58,533 |
| 2017-02-03 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,375 | 42.56 | 58,520 |
| 2017-02-03 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,375 | 42.57 | 58,533 |
| 2017-02-03 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,500 | 42.55 | 63,824 |
| 2017-02-03 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,500 | 42.50 | 63,750 |
| 2017-02-03 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,125 | 42.55 | 132,968 |
| 2017-02-01 | Rastetter William H (Director) | Sale | 10,750 | 42.28 | 454,510 |
| 2017-02-01 | Rastetter William H (Director) | Option Ex | 25,000 | 2.17 | 54,250 |
| 2017-01-17 | Gano Kyle (Chief Business Development Officer) | Sale | 1,625 | 40.65 | 66,056 |
| 2017-01-17 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 40.63 | 66,023 |
| 2017-01-17 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 40.63 | 66,023 |
| 2017-01-17 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 40.65 | 71,137 |
| 2017-01-17 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 40.66 | 71,155 |
| 2017-01-17 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,750 | 40.65 | 152,437 |
| 2017-01-10 | Gano Kyle (Chief Business Development Officer) | Sale | 1,250 | 43.37 | 54,212 |
| 2017-01-10 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 1,625 | 43.39 | 70,508 |
| 2017-01-10 | Bozigian Haig P. (Chief Development Officer) | Sale | 1,625 | 43.37 | 70,476 |
| 2017-01-10 | Coughlin Timothy P (Chief Financial Officer) | Sale | 1,750 | 43.37 | 75,897 |
| 2017-01-10 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 1,750 | 43.35 | 75,862 |
| 2017-01-10 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,750 | 43.28 | 162,300 |
| 2016-12-23 | Gorman Kevin Charles (President and CEO) | Option Ex | 9,100 | 2.59 | 23,569 |
| 2016-11-15 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 25,000 | 52.84 | 1,321,000 |
| 2016-09-01 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 9,000 | 50.00 | 450,000 |
| 2016-09-01 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 9,000 | 15.45 | 139,050 |
| 2016-08-15 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 12,500 | 48.73 | 609,125 |
| 2016-08-08 | Nevinny Corinne H (Director) | Sale | 5,000 | 48.54 | 242,700 |
| 2016-05-31 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 12,500 | 50.00 | 625,000 |
| 2016-05-25 | Pops Richard F (Director) | Sale | 15,000 | 46.72 | 700,800 |
| 2016-05-16 | Obrien Christopher Flint (Chief Medical Officer) | Sale | 25,000 | 45.00 | 1,125,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX,
CIK number 914475) see
the Securities and Exchange Commission (SEC) website.